MAM
NGNE icon

Martingale Asset Management’s Neurogene NGNE Stock Holding History

Martingale Asset Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-691
Closed -$195K – 884
2020
Q4 		$195K Sell
691
-2,255
-77% -$551K ﹤0.01% 841
2020
Q3 		$707K Buy
+2,946
New +$714K 0.01% 722

Other funds holding NGNE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Martingale Asset Management's NGNE Position: Q1 2021 in Review

Martingale Asset Management sold out of Neurogene (NGNE) in Q1 2021, closing a stake of 691 shares — an estimated $195K sold.

Martingale Asset Management first reported a position in NGNE in Q3 2020 and held it in 2 quarters. The position peaked at $707K in Q3 2020. 82 funds tracked by Wall St. Rank hold NGNE as of Q1 2021.

  • Martingale Asset Management reported no remaining Neurogene position as of Q1 2021 after selling out during the quarter.
  • Martingale Asset Management sold 691 Neurogene shares in Q1 2021, an estimated $195K.
  • Martingale Asset Management first reported a position in Neurogene in Q3 2020 and held it in 2 quarters.
  • Martingale Asset Management's Neurogene position peaked at $707K in Q3 2020.
  • 82 funds tracked by Wall St. Rank held Neurogene as of Q1 2021.

Based on Martingale Asset Management's 13F filing for Q1 2021, filed 13 May 2021.